Nivalis Cystic Fibrosis Candidate Garners FDA Fast Track Status

Nivalis Therapeutics has snapped up FDA fast track designation for its N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator protein.

Data is expected from the candidate’s Phase 2 trial in the second half of 2016. The treatment also recently won orphan drug status for cystic fibrosis.